Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Astellas Pharma Inc
This clinical trial is designed to include two parts:
Part 1: Assessment of feasibility and safety of administering YM155 in combination with docetaxel and prednisone in subjects with hormone refractory prostate cancer (HRPC) \[ ENROLLMENT COMPLETED \]
Part 2: Assessment of feasibility and safety of administering YM155 in combination with docetaxel in subjects with solid tumors (except HRPC).
This registration has been updated to reflect the design requirements of PART 2.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Part 1:
Male subjects with histologically or cytologically confirmed adenocarcinoma of the prostate with clinical or radiological evidence of metastatic disease.
Part 2:
Subjects with histologically and cytologically confirmed solid tumors with measurable disease (except HRPC).
You may not be if
Radiation therapy within 4 weeks of the start of study drug
Clareo Health | An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors
